We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.00 | -0.51% | 1,356.50 | 1,356.00 | 1,356.50 | 1,370.00 | 1,353.00 | 1,365.00 | 5,013,886 | 16:29:58 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 11.41 | 56.52B |
From Jan 2020 to Jan 2025
By Cecilia Butini
The European Commission said Wednesday that it has signed a contract with GlaxoSmithKline PLC for the supply of a monoclonal antibody that can be used for the treatment of Covid-19.
The Commission said the contract is a procurement framework contract for sotrovimab, a drug developed by GlaxoSmithKline in collaboration with VIR Biotechnology Inc.
The treatment is part of a portfolio of five promising therapeutics which the Commission singled out in June as part of its Covid-19 therapeutics strategy, and is currently under rolling review by the European Medicines Agency.
"Sotrovimab can be used for the treatment of coronavirus patients with mild symptoms who do not require supplemental oxygen, but who are at high risk for severe COVID-19," according to the Commission.
According to the agreement with GlaxoSmithKline, member states can purchase the drug once it has received either emergency authorization in the state, or a marketing authorization from the EU Medicines Agency.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
July 28, 2021 06:49 ET (10:49 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
